Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover study of GME751 (pembrolizumab biosimilar) for melanoma and NSCLC
2024-513160-25-00Phase 3Authorised
- Sponsor
- Hexal AG
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, open-label trial of pembrolizumab in melanoma and non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Hexal AG. Primary endpoints: Primary safety endpoint – melanoma cohort and Primary safety endpoint – NSCLC cohort. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513160-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513160-25-00.